TBN is a first-in-class small molecule drug designed to treat ischemic stroke, diabetic kidney disease, and amyotrophic lateral sclerosis by crossing the blood-brain barrier and modulating mitochondrial function and autophagy.

MN-08 is a first-in-class small molecule drug targeting Alzheimer's disease, vascular dementia, and pulmonary arterial hypertension by antagonizing NMDA receptors and releasing nitric oxide to improve cerebral and pulmonary blood flow.